Business
Collaboration advances Steriwave for ICU Market
Collaboration advances Steriwave for ICU Market.
About this update from Ondine Biomedical, Inc.
[{"type":"text","content":"\n\nONDINE BIOMEDICAL INC.\n(\"Ondine Biomedical\", \"Ondine\", or the \"Company\")\n \nCollaboration advances Steriwave for ICU Market\n \nRoyal Columbian Hospital Foundation's Advancing Innovation in Medicine (AIM) division supports Steriwave ICU use with clinical trials at Royal Columbian Hospital\n \n· Treatment of patients in intensive care units (ICUs) would significantly expand Ondine's market opportunity.\n· Infection prevention is a top priority in ICUs as they face higher infection rates, more fragile and sicker patients, and bed capacity shortages.\n \nOndine Biomedical Inc. (LON: OBI), the Canadian life sciences company at the forefront of light-activated antimicrobial treatments, is pleased to announce a research collaboration with the Royal Columbian Hospital (RCH) Foundation's Advancing Innovation in Medicine (AIM) division. \n \nThis research collaboration, in support of Steriwave® use in the intensive care unit (ICU), is investigating Steriwave's impact on infection prevention and patient outcomes in critical care settings. It initially involves a 320-patient pilot with the potential for a subsequent multicentre trial with up to 2,000 patients depending on the results of the initial phase. The C$855,000 study will be funded by the RCH Foundation's AIM division which will support the ICU clinical development work in a services-for-shares collaboration to help accelerate the use of photodisinfection in the ICU.\n \nRoyal Columbian Hospital, a hospital within BC's Fraser Health Authority, will be the first to trial Ondine's Steriwave nasal decolonization technology to prevent infections in ICUs. The study will be led by ICU physician Dr. Steven Reynolds and his research team at RCH. The purpose of this strategic initiative is to integrate Ondine's Steriwave, a proven nasal decolonization therapy, into ICU infection control and workflow protocols to determine the impact of rapid broad spectrum nasal decolonization on ICU infection rates, impact on length of stay and mortality rates.\n \nDr. Steven Reynolds, founder and executive lead of the RCH AIM division, stated:\n\"By eradicating bacteria in the nose without harming the nasal epithelium, we can help prevent the rapid colonization of ICU patients with multidrug-resistant bacteria. This is...